JP2019513014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513014A5 JP2019513014A5 JP2018547940A JP2018547940A JP2019513014A5 JP 2019513014 A5 JP2019513014 A5 JP 2019513014A5 JP 2018547940 A JP2018547940 A JP 2018547940A JP 2018547940 A JP2018547940 A JP 2018547940A JP 2019513014 A5 JP2019513014 A5 JP 2019513014A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- scfv
- polypeptide
- linker
- pair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 106
- 229920001184 polypeptide Polymers 0.000 claims description 104
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 104
- 102000036639 antigens Human genes 0.000 claims description 68
- 108091007433 antigens Proteins 0.000 claims description 68
- 239000000427 antigen Substances 0.000 claims description 67
- 239000004365 Protease Substances 0.000 claims description 56
- 108091005804 Peptidases Proteins 0.000 claims description 54
- 125000005647 linker group Chemical group 0.000 claims description 49
- 238000003776 cleavage reaction Methods 0.000 claims description 43
- 230000007017 scission Effects 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 9
- 239000013604 expression vector Substances 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000005600 Cathepsins Human genes 0.000 claims 1
- 108010084457 Cathepsins Proteins 0.000 claims 1
- 102100035139 Folate receptor alpha Human genes 0.000 claims 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims 1
- 108010091175 Matriptase Proteins 0.000 claims 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- -1 mepurin Proteins 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 description 45
- 235000019419 proteases Nutrition 0.000 description 44
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 20
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 20
- 239000000203 mixture Substances 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 4
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108091007504 ADAM10 Proteins 0.000 description 1
- 108091007507 ADAM12 Proteins 0.000 description 1
- 101000642536 Apis mellifera Venom serine protease 34 Proteins 0.000 description 1
- 101100208110 Arabidopsis thaliana TRX4 gene Proteins 0.000 description 1
- 108091005504 Asparagine peptide lyases Proteins 0.000 description 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 101100372806 Caenorhabditis elegans vit-3 gene Proteins 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 102000003902 Cathepsin C Human genes 0.000 description 1
- 108090000267 Cathepsin C Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102000004178 Cathepsin E Human genes 0.000 description 1
- 108090000611 Cathepsin E Proteins 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 101100425276 Dictyostelium discoideum trxD gene Proteins 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 description 1
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 description 1
- 108700033317 EC 3.4.23.12 Proteins 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 1
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 description 1
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 description 1
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 description 1
- 101000633445 Homo sapiens Structural maintenance of chromosomes protein 2 Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 102000003843 Metalloendopeptidases Human genes 0.000 description 1
- 108090000131 Metalloendopeptidases Proteins 0.000 description 1
- 102000005612 Metalloexopeptidases Human genes 0.000 description 1
- 108010045057 Metalloexopeptidases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 101100154863 Mus musculus Txndc2 gene Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 102100029540 Structural maintenance of chromosomes protein 2 Human genes 0.000 description 1
- 101710135785 Subtilisin-like protease Proteins 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 108091005501 Threonine proteases Proteins 0.000 description 1
- 102000035100 Threonine proteases Human genes 0.000 description 1
- 102000057032 Tissue Kallikreins Human genes 0.000 description 1
- 108700022175 Tissue Kallikreins Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000350 actinidain Proteins 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002901 elastaselike Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108010020708 plasmepsin Proteins 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022081366A JP7293456B2 (ja) | 2016-03-08 | 2022-05-18 | 誘導性結合タンパク質及びその使用方法 |
| JP2023093681A JP2023123519A (ja) | 2016-03-08 | 2023-06-07 | 誘導性結合タンパク質及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305092P | 2016-03-08 | 2016-03-08 | |
| US62/305,092 | 2016-03-08 | ||
| PCT/US2017/021435 WO2017156178A1 (en) | 2016-03-08 | 2017-03-08 | Inducible binding proteins and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022081366A Division JP7293456B2 (ja) | 2016-03-08 | 2022-05-18 | 誘導性結合タンパク質及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513014A JP2019513014A (ja) | 2019-05-23 |
| JP2019513014A5 true JP2019513014A5 (https=) | 2020-04-16 |
| JP7195927B2 JP7195927B2 (ja) | 2022-12-26 |
Family
ID=59789722
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547940A Active JP7195927B2 (ja) | 2016-03-08 | 2017-03-08 | 誘導性結合タンパク質及びその使用方法 |
| JP2022081366A Active JP7293456B2 (ja) | 2016-03-08 | 2022-05-18 | 誘導性結合タンパク質及びその使用方法 |
| JP2023093681A Pending JP2023123519A (ja) | 2016-03-08 | 2023-06-07 | 誘導性結合タンパク質及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022081366A Active JP7293456B2 (ja) | 2016-03-08 | 2022-05-18 | 誘導性結合タンパク質及びその使用方法 |
| JP2023093681A Pending JP2023123519A (ja) | 2016-03-08 | 2023-06-07 | 誘導性結合タンパク質及びその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180134789A1 (https=) |
| EP (1) | EP3426689A4 (https=) |
| JP (3) | JP7195927B2 (https=) |
| KR (2) | KR20230041739A (https=) |
| CN (1) | CN109071667A (https=) |
| AU (1) | AU2017229687A1 (https=) |
| BR (1) | BR112018068189A2 (https=) |
| CA (1) | CA3016165A1 (https=) |
| IL (1) | IL261432B2 (https=) |
| MA (1) | MA43816A (https=) |
| MX (1) | MX2018010824A (https=) |
| SG (1) | SG11201807548SA (https=) |
| TW (2) | TW202302631A (https=) |
| WO (1) | WO2017156178A1 (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| ES2873846T5 (en) | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| CN116987189A (zh) | 2016-05-20 | 2023-11-03 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CN110198955A (zh) | 2016-11-23 | 2019-09-03 | 哈普恩治疗公司 | 前列腺特异性膜抗原结合蛋白质 |
| EP3544629A4 (en) | 2016-11-23 | 2020-06-17 | Harpoon Therapeutics, Inc. | PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF |
| WO2018160671A1 (en) * | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Targeted checkpoint inhibitors and methods of use |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| EP3619234A4 (en) * | 2017-05-03 | 2021-05-26 | Harpoon Therapeutics, Inc. | COMPOSITIONS AND PROCEDURES FOR ADOPTIVE CELL THERAPIES |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| IL302613B2 (en) | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| WO2019051122A2 (en) | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN118059232A (zh) | 2017-11-01 | 2024-05-24 | 南特生物科学公司 | 阻断emt途径并克服癌干细胞的il8 |
| CN110218253B (zh) * | 2018-03-02 | 2020-12-04 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb14及其制备方法与应用 |
| CN110218256B (zh) * | 2018-03-02 | 2020-12-08 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb29及其制备方法与应用 |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| US20210269530A1 (en) * | 2018-05-14 | 2021-09-02 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| KR20210020903A (ko) * | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| EP3810624A4 (en) | 2018-06-22 | 2022-07-06 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| WO2020033837A1 (en) | 2018-08-09 | 2020-02-13 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| SG11202103022WA (en) * | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| EP3917542A4 (en) * | 2019-01-29 | 2023-03-08 | Gritstone bio, Inc. | MULTISPECIFIC BINDING PROTEINS |
| US20220144949A1 (en) * | 2019-03-05 | 2022-05-12 | Takeda Pharmaceutical Limited Company | CONDITIONALLY ACTIVATED BINDING PROTEINS CONTAINING Fc REGIONS AND MOIETIES TARGETING TUMOR ANTIGENS |
| WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| US12516128B2 (en) | 2019-05-14 | 2026-01-06 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| WO2021097060A1 (en) * | 2019-11-13 | 2021-05-20 | Harpoon Therapeutics, Inc. | Pro immune modulating molecule comprising a clustering moiety |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| MX2022007202A (es) * | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
| CN114829408B (zh) * | 2019-12-20 | 2024-01-26 | 山东博安生物技术股份有限公司 | 用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂 |
| EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc. | PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY |
| US20210301015A1 (en) * | 2020-01-17 | 2021-09-30 | Aetio Biotherapy, Inc. | Pro-antibody that reduces off-target toxicity |
| CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| BR112022019841A2 (pt) | 2020-04-09 | 2022-12-06 | Cytomx Therapeutics Inc | Composições contendo anticorpos ativáveis |
| WO2022002112A1 (en) | 2020-07-01 | 2022-01-06 | Shandong Boan Biotechnology Co., Ltd. | Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody |
| US20240409617A1 (en) | 2020-07-03 | 2024-12-12 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
| PE20230856A1 (es) | 2020-08-17 | 2023-05-29 | Takeda Pharmaceuticals Co | Proteinas de union restringidas activadas de forma condicional |
| CA3184037A1 (en) * | 2020-08-18 | 2022-02-24 | Onchilles Pharma, Inc. | Modified serine protease proproteins |
| EP4199947A4 (en) | 2020-08-18 | 2024-10-16 | Onchilles Pharma, Inc. | Modified porcine pancreatic elastase proteins |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| TW202304998A (zh) | 2021-04-06 | 2023-02-01 | 日商武田藥品工業股份有限公司 | 使用限制性條件活化之結合蛋白的治療方法 |
| EP4334354A1 (en) | 2021-05-06 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
| WO2023034288A1 (en) | 2021-08-31 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treatment of autoimmune disorders and cancer |
| EP4436998A1 (en) | 2021-11-24 | 2024-10-02 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
| WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
| CA3241407A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
| KR20250099103A (ko) | 2022-08-15 | 2025-07-01 | 다나-파버 캔서 인스티튜트 인크. | Cldn4에 대한 항체 및 이의 사용 방법 |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| EP4619427A1 (en) * | 2022-11-15 | 2025-09-24 | F. Hoffmann-La Roche AG | Recombinant binding proteins with activatable effector domain |
| WO2025237931A1 (en) * | 2024-05-15 | 2025-11-20 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2522586C (en) * | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| DE602004030811D1 (de) * | 2003-10-16 | 2011-02-10 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| MX340556B (es) * | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
| US20120225081A1 (en) | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| DK2714733T3 (da) * | 2011-05-21 | 2019-05-06 | Macrogenics Inc | Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3 |
| EP2726502A1 (en) | 2011-07-01 | 2014-05-07 | Bayer Intellectual Property GmbH | Relaxin fusion polypeptides and uses thereof |
| AU2013226340B2 (en) | 2012-02-27 | 2017-06-22 | Ablynx N.V. | CX3CR1-binding polypeptides |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| EP2820047B1 (en) | 2012-03-01 | 2018-04-25 | Amgen Research (Munich) GmbH | Long life polypeptide binding molecules |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| ES2897579T3 (es) * | 2013-06-10 | 2022-03-01 | Dana Farber Cancer Inst Inc | Métodos y composiciones para reducir la inmunosupresión por células tumorales |
| JP6775422B2 (ja) * | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| ES2873846T5 (en) | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| WO2020033837A1 (en) * | 2018-08-09 | 2020-02-13 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
-
2017
- 2017-03-08 KR KR1020237005284A patent/KR20230041739A/ko not_active Ceased
- 2017-03-08 CN CN201780028480.4A patent/CN109071667A/zh active Pending
- 2017-03-08 AU AU2017229687A patent/AU2017229687A1/en not_active Abandoned
- 2017-03-08 SG SG11201807548SA patent/SG11201807548SA/en unknown
- 2017-03-08 IL IL261432A patent/IL261432B2/en unknown
- 2017-03-08 TW TW111119065A patent/TW202302631A/zh unknown
- 2017-03-08 JP JP2018547940A patent/JP7195927B2/ja active Active
- 2017-03-08 BR BR112018068189-0A patent/BR112018068189A2/pt active Search and Examination
- 2017-03-08 WO PCT/US2017/021435 patent/WO2017156178A1/en not_active Ceased
- 2017-03-08 EP EP17764037.2A patent/EP3426689A4/en active Pending
- 2017-03-08 CA CA3016165A patent/CA3016165A1/en active Pending
- 2017-03-08 MA MA043816A patent/MA43816A/fr unknown
- 2017-03-08 KR KR1020187029014A patent/KR102501921B1/ko active Active
- 2017-03-08 TW TW106107861A patent/TW201808990A/zh unknown
- 2017-03-08 MX MX2018010824A patent/MX2018010824A/es unknown
- 2017-10-06 US US15/727,423 patent/US20180134789A1/en not_active Abandoned
-
2022
- 2022-05-18 JP JP2022081366A patent/JP7293456B2/ja active Active
-
2023
- 2023-06-07 JP JP2023093681A patent/JP2023123519A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513014A5 (https=) | ||
| JP7490853B2 (ja) | 拘束され、条件的に活性化された結合タンパク質 | |
| US20210355219A1 (en) | Conditionally activated target-binding molecules | |
| JP2021087429A5 (https=) | ||
| JP2023540533A (ja) | ヒト血清アルブミンドメインを有する、制約され、条件付きで活性化された結合タンパク質構築物 | |
| JP2025163013A (ja) | 拘束され、条件的に活性化された結合タンパク質 | |
| US20240026011A1 (en) | Constrained conditionally activated binding proteins | |
| US12590159B2 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| US20260055205A1 (en) | Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same | |
| US12128102B2 (en) | Constrained conditionally activated binding proteins | |
| JPWO2021236676A5 (https=) | ||
| US20230340159A1 (en) | Constrained conditionally activated binding proteins | |
| CN121949565A (zh) | 靶向表皮生长因子受体的组合物及其制备和使用方法 | |
| JPWO2023192973A5 (https=) | ||
| WO2026024863A2 (en) | Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists | |
| HK40032913A (en) | Constrained conditionally activated binding proteins | |
| RU2020123264A (ru) | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения |